INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,082,502 | -17.8% | 78,374 | -0.1% | 0.03% | -11.4% |
| Q2 2023 | $4,967,074 | +37.5% | 78,444 | +17.6% | 0.04% | +29.6% |
| Q1 2023 | $3,612,780 | -30.7% | 66,718 | -32.2% | 0.03% | -32.5% |
| Q4 2022 | $5,211,244 | +12.1% | 98,474 | -1.5% | 0.04% | +5.3% |
| Q3 2022 | $4,650,000 | -20.5% | 99,930 | -2.4% | 0.04% | -13.6% |
| Q2 2022 | $5,846,000 | -11.4% | 102,414 | -5.0% | 0.04% | +2.3% |
| Q1 2022 | $6,599,000 | +18.3% | 107,838 | +1.2% | 0.04% | +22.9% |
| Q4 2021 | $5,577,000 | -10.6% | 106,559 | -36.3% | 0.04% | -16.7% |
| Q3 2021 | $6,237,000 | -10.1% | 167,311 | -1.6% | 0.04% | -8.7% |
| Q2 2021 | $6,939,000 | +20.1% | 169,994 | -0.2% | 0.05% | +17.9% |
| Q1 2021 | $5,779,000 | -5.3% | 170,333 | -11.2% | 0.04% | -13.3% |
| Q4 2020 | $6,101,000 | – | 191,850 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |